Document is current
Any future updates will be listed below
-
Authors
Li, Benjamin Xiaoyi
Dai, Xiangrong
Xu, Xiaohong Ruby
Adili, Reheman
Neves, Miguel Antonio Dias
Lei, Xi
Shen, Chuanbin
Zhu, Guangheng
Wang, Yiming
Zhou, Hui
Hou, Yan
Ni, Tiffany
Pasman, Yfke
Yang, Zhongqiang
Qian, Fang
Zhao, Yanan
Gao, Yongxiang
Liu, Jing
Teng, Maikun
Marshall, Alexandra H.
Cerenzia, Eric G.
Li, Mandy Lokyee
Ni, Heyu
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01588132 at ClinicalTrials.govDocuments that mention this clinical trial
In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα
https://doi.org/10.1038/s41598-021-91165-8
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (MOP 119540, Foundation grant 389035)
Canadian Institutes of Health Research and National Natural Science Foundation of China
Heart and Stroke Foundation of Canada
Canadian Foundation for Innovation
Lee’s Pharmaceutical Holdings limited
Heart and Stroke/Richard Lewar Centre of Excellence Studentship Award
Meredith and Malcolm Silver Scholarship in Cardiovascular Studies
Postdoctoral Fellowship award from Canadian Blood Services Centre for Innovation
Graduate Fellowship from Canadian Blood Services Centre for Innovation
State Scholarship Fund from China Scholarship Council
Canadian Institutes of Health Research (CIHR) Master studentship award
- License Information
-
More Information
Article History
Received: 16 July 2020
Accepted: 18 May 2021
First Online: 3 June 2021
Competing interests
: The authors declare the following competing interests: this research and the work in Lei et al.<sup>21</sup> and Hou et al.<sup>35</sup> was partially funded by Lee’s Pharmaceutical Holdings limited. B.X.L., X.D., Z.Y., F.Q., and M.L.L. are supported by Lee’s Pharmaceutical Holdings Limited and/or Zhaoke Pharmaceutical Co. Limited. The other authors declare they have no actual or potential competing interests.
